Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06512597 · ClinicalTrials.gov registry record · NA

Behavioral Therapy for Crohn's Disease

A NA study of Crohn's Disease, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
NA
Development phase
170
Enrollment target
2
Study locations

NCT06512597: Recruiting NA study of Crohn's Disease, sponsored by Icahn School of Medicine at Mount Sinai.

NCT06512597 is a NA study of Crohn's Disease that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 170 participants, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06512597, a NA study of Crohn's Disease, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
NA
Development phase
170 participants
Enrollment target
2
Study locations

Study Summary

People living with Crohn's disease (CD) experience psychological and emotional symptoms, in addition to known chronic and disabling physical symptoms, which prevent them from living their life to the fullest (flourishing). Depression and anxiety are experienced by 30% of people living with CD and 60% of inflammatory bowel disease (IBD) patients continue to report chronic pain, stress, sleeplessness, and fatigue, even when they are "objectively" in remission. Psychological stress has been endorsed by 70% of patients with IBD as a key trigger for disease activity which is not surprising given the significance of the gut-brain-microbiome axis, the close communication between the enteric and autonomic nervous systems, and the role of the hypothalamic-pituitary axis and its neuroendocrine and immune functions in the expression of GI symptoms. Interestingly, up to 85% of patients with CD also endorse the positive impact of effective coping skills on disease course. The PI's prior work has suggested that early provision of effective coping strategies, offered at the time of diagnosis or more precisely, immediately prior to biologic medication initiation, could potentially result in faster healing and improved well-being, likely through the combination of 1) physiological mitigation of the stress response and optimization of the gut-brain-microbiome axis; and 2) promotion of effective coping and disease self-management behaviors that promote psychological flourishing despite disease. Unfortunately, to date, early effective psychosocial care has been limited by concerns over reimbursement for psychological services, access to qualified IBD mental health professionals, and the lack of a standardized methodology focused on the brain-gut stress response and how to assess, monitor, communicate and maintain tight control over both physical and emotional well-being. CATHARSIS is a rigorous, placebo-controlled, randomized controlled trial of coping strategies plus medication for 17

Primary Outcome

Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale A series of person-centered measures that evaluate and monitor physical, mental, and social health in adults and children. 10-item patient-reported questionnaire. standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient.

Conditions Studied

Interventions

  • BEHAVIORAL Primary Intervention for Combination Therapy - IBD Coping Strategies Program
  • BEHAVIORAL Time and Attention Control - IBD Support Program

Study Locations (2)

New York

  • Icahn School of Medicine at Mount Sinai - New York
  • New York Gastroenterology Associates - New York

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2024-11-01
Est. Completion 2028-07-30
Phase NA

What NCT06512597 shows while recruiting

NCT06512597 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Primary Intervention for Combination Therapy - IBD Coping Strategies Program is the first listed.

NCT06512597 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06512597 about?

NCT06512597 is a clinical study titled "Behavioral Therapy for Crohn's Disease". People living with Crohn's disease (CD) experience psychological and emotional symptoms, in addition to known chronic and disabling physical symptoms, which prevent them from living their life to the fullest (flourishing). Depression and anxiety are experienced by 30% of people living with CD and 60...

What is the current status of trial NCT06512597?

This trial is currently recruiting. It is a NA study. The enrollment target is 170 participants. The study started on 2024-11-01. Estimated completion is 2028-07-30.

What conditions does trial NCT06512597 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT06512597?

The interventions under investigation include: Primary Intervention for Combination Therapy - IBD Coping Strategies Program (BEHAVIORAL), Time and Attention Control - IBD Support Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06512597?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06512597 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06512597's enrollment target sits among peer trials

170 57th of 105 higher than 49 of 105 other Crohn's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02016430 · 170 participants · NA

    Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

  • NCT02621021 · 170 participants · Phase 2

    A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

  • NCT04094701 · 170 participants · NA

    Hip Arthroscopy Postoperative Opioid Demands

  • NCT04166409 · 170 participants · Phase 3

    A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06512597, the US trial registry maintained by the National Library of Medicine. NCT06512597 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.